ALK rearrangement

Due to rapid enrollment, the target sample size was expanded to 28 patients. The primary endpoint is objective response rate confirmed by central assessment; secondary endpoints include duration of response, progression-free survival, overall survival, and safety.Clinical trial registration: jRCT2041210148 (https://jrct.mhlw.go.jp).

P=N/A, N=240, Completed, Bristol-Myers Squibb

P1, N=320, Recruiting, BioNTech SE | N=156 --> 320

The patient received two cycles of nab-paclitaxel and carboplatin, and repeated CT scan showed disease progression. Her treatment was subsequently changed to glumetinib plus iruplinalkib and she died less than one month later...Co-amplification of the multiple genes may be involved in aggressive disease and drug resistance, which should be considered in future clinical trials and clinical management. Early broad-panel next-generation sequencing testing in LUSCC patients who are never-smokers may help guide management for patients who have complex mutational profiles.

The study underscores the importance of integrating NGS-based molecular testing with PD-L1 evaluation for personalised management of NSCLC. Distinct patterns of PD-L1 expression across molecular subtypes, particularly lower in EGFR-mutated tumours and higher in KRAS-mutated tumours, underscore the need for tailored therapeutic strategies and informed sequencing of targeted therapies and immunotherapies.

These findings demonstrate that IHC-based screening followed by confirmatory FISH provides a rapid and cost-effective strategy for identifying cases of non-LCH with JXG morphology harboring actionable kinase alterations. Integration of IHC, FISH, and NGS represents a practical and complementary diagnostic strategy to guide precision therapy in this clinically diverse histiocytic disorder.

Finally, nutritional management is discussed, as is the role of adapted physical activity. In conclusion, this article highlights the importance of proactive monitoring and management of adverse cardiovascular events in patients treated with lorlatinib.

P4, N=41, Active, not recruiting, Guangdong Association of Clinical Trials | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Apr 2026

P3, N=218, Completed, Sandoz | Suspended --> Completed

P1/2, N=45, Recruiting, Instituto Nacional de Cancerologia de Mexico | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

P1/2, N=56, Recruiting, Joshua Palmer | Trial completion date: Jun 2027 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2028